Cargando…

Promising Role of Circulating Tumor Cells in the Management of SCLC

SIMPLE SUMMARY: Despite the recent approval of immune-checkpoint inhibitors, therapeutic strategies for the treatment of small-cell lung cancer (SCLC) patients remained unchanged for decades. The aggressiveness of the disease and the lack of active treatments underlie the need for the identification...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Luca, Antonella, Gallo, Marianna, Esposito, Claudia, Morabito, Alessandro, Normanno, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122820/ https://www.ncbi.nlm.nih.gov/pubmed/33922300 http://dx.doi.org/10.3390/cancers13092029

Ejemplares similares

Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring
por: Barchiesi, Vittoria, et al.
Publicado: (2021)

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls
por: Esposito Abate, Riziero, et al.
Publicado: (2020)

Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management
por: Sacco, Alessandra, et al.
Publicado: (2020)

Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC
por: Smith, Jarrod T., et al.
Publicado: (2020)

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion
por: Morabito, Alessandro, et al.
Publicado: (2022)

The promise of circulating tumor cell analysis in cancer management
por: Mateo, Joaquin, et al.
Publicado: (2014)

Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications
por: Pasquale, Raffaella, et al.
Publicado: (2020)

TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC)
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells
por: Gallo, Marianna, et al.
Publicado: (2022)

Sonic Hedgehog in SCLC
por: Laukkanen, Mikko O., et al.
Publicado: (2015)

Pathology and Classification of SCLC
por: Raso, Maria Gabriela, et al.
Publicado: (2021)

The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
por: Cortellini, Alessio
Publicado: (2020)

RNA-seq analysis reveals significant effects of EGFR signalling on the secretome of mesenchymal stem cells
por: De Luca, Antonella, et al.
Publicado: (2014)

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
por: Saltos, Andreas, et al.
Publicado: (2020)

Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics
por: Roma, Cristin, et al.
Publicado: (2022)

Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology
por: Roma, Cristin, et al.
Publicado: (2013)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC
por: Mohan, Sumitra, et al.
Publicado: (2020)

Killing SCLC: insights into how to target a shapeshifting tumor
por: Sutherland, Kate D., et al.
Publicado: (2022)

Circulating Tumor Cells: A Promising Biomarker in the Management of Nasopharyngeal Carcinoma
por: Wu, Jiangtao, et al.
Publicado: (2021)

Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
por: Vecchiarelli, Silvia, et al.
Publicado: (2018)

Surgery in Small-Cell Lung Cancer
por: Martucci, Nicola, et al.
Publicado: (2021)

Small Cell Lung Cancer (SCLC) Presenting as Acute Pancreatitis: The Role of Hypercalcemia
por: Tan, Jessica, et al.
Publicado: (2012)

RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells
por: Gallo, Marianna, et al.
Publicado: (2018)

What's New in SCLC? A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Novel Silver Complexes Based on Phosphanes and Ester Derivatives of Bis(pyrazol-1-yl)acetate Ligands Targeting TrxR: New Promising Chemotherapeutic Tools Relevant to SCLC Management
por: Pellei, Maura, et al.
Publicado: (2023)

Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance: Understanding SCLC heterogeneity and plasticity in metastasis and chemoresistance
por: Jin, Yujuan, et al.
Publicado: (2023)

Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells
por: Chen, Huanhuan Joyce, et al.
Publicado: (2019)

The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report
por: Pearsall, Sarah M., et al.
Publicado: (2020)

The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
por: Men, Yu, et al.
Publicado: (2017)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)

Tumor and host characteristics of small cell lung cancer (SCLC) in U.S. community oncology practice
por: Richards, Donald, et al.
Publicado: (2015)

Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
por: Carpentier, Joséphine, et al.
Publicado: (2022)

Impact of Socioeconomic Factors on Overall Survival in SCLC
por: Roof, Logan, et al.
Publicado: (2022)

cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?
por: Normanno, Nicola, et al.
Publicado: (2020)

DT-diaphorase activity in NSCLC and SCLC cell lines: a role for fos/jun regulation
por: Kepa, J K, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_hvmbogepd335l5prc1mo6vj5gh